[EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE EN TANT QU'INHIBITEURS D'ANGIOGENESE
申请人:ASTRAZENECA AB
公开号:WO2005014582A1
公开(公告)日:2005-02-17
The present invention relates to compounds of the Formula (I): wherein: ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N and S; is -O- -NH- or -S-; is 0, 1, 2, 3, 4 or 5; is 0, 1, 2 or 3; and R2 and R1 are as defined herein; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm blooded animals; processes for the preparation of such compounds; pharmaceutical compositions containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
本发明涉及以下式(I)的化合物:其中:环C是一个8、9、10、12或13成员的双环或三环基团,该基团可以是饱和的或不饱和的,可以是芳香的或非芳香的,并且可以选择性地包含1-3个从O、N和S中独立选择的杂原子;是-O-、-NH-或-S-;是0、1、2、3、4或5;是0、1、2或3;R2和R1如本文所定义;及其盐;它们在制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物中的用途;制备这种化合物的方法;含有式(I)的化合物或其药学上可接受的盐的药物组合物以及通过给予式(I)的化合物或其药学上可接受的盐来治疗涉及血管生成的疾病状态的方法。式(I)的化合物抑制VEGF的作用,在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值的特性。